Characterization of Xenograft Models of Childhood Cancers

儿童癌症异种移植模型的表征

• 批准号: 7733098
• 负责人: Javed KHAN
• 金额: $ 5.44万
• 依托单位: DIVISION OF BASIC SCIENCES - NCI
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/7733098
• 关键词: Antineoplastic Agents; Cancer Model; Cancer Therapy Evaluation Program; Cell Line; Cells; Cessation of life; Child; Childhood; Children' s Oncology Group; Clinical; Collaborations; Communities; DNA Microarray Chip; DNA Microarray format; Development; Funding; Genes; Grant; Institutes; Malignant Childhood Neoplasm; Malignant Neoplasms; Modeling; Molecular Target; National Cancer Institute; Outcome; Pathway interactions; Pharmacologic Substance; Phase; Pre-Clinical Model; Preclinical Testing; Protein Array; Protein Microchips; Proteins; Purpose; Qualifying; Reagent; Research; Research Personnel; Resources; Signal Pathway; Signal Transduction; Testing; Tissues; Translations; Xenograft Model; Xenograft procedure; cDNA Arrays; drug development; improved; novel; novel therapeutics; pre-clinical; programs; therapeutic target

This array project is being conducted in collaboration with the Children's Oncology Group (COG) Phase 1 Consortium and the Cancer Therapy Evaluation Program (CTEP) and was partially externally funded by a grant from the NCI. It is in accord with some of the requirement embodied in the "Best Pharmaceuticals for Children Act" which stated that "the Director of the National Cancer Institute shall expand, intensify, and coordinate the activities of the Institute with respect to research on the development of preclinical models to evaluate which therapies are likely to be effective for treating pediatric cancer." There are three main objectives of this project. (1) To determine which of the currently utized pediatric cancer models (xenograft) most closely resembles the cancer(s) of origin by cDNA microarrays. (2) To develop tissue and cell microarrays and protein lysate arrays of this preclinical panel, for the purpose of identifying cancer-related molecular targets and signaling pathways that may be therapeutically exploited to improve the outcome for children that suffer from cancer. (3) To provide these tissue and protein arrays as reagents to qualified investigators in the extra- and intra-mural research community. This project will facilitate pediatric cancer drug development by identifying the best xenograft models that are the most similar to the cancer of origin, and will be a resource to use in identifying molecular targets and cell signal profiles, and for subsequent testing new anti-cancer agents for their potential activity against childhood cancers. This resource has the potential to increase the pace of new therapeutic target discovery for childhood cancers and to facilitate the clinical use of new molecularly targeted agents active against childhood cancers. targets such as death pathway genes, uniquely expressed in these cancers.

该阵列项目正在与儿童肿瘤学集团（COG）1阶段联盟和癌症治疗评估计划（CTEP）合作进行，并由NCI的赠款部分在外部资助。它符合“儿童最佳药物法案”中体现的一些要求，该要求“国家癌症研究所的主任应扩展，加强和协调研究所在研究临床前模型的研究中的活动，以评估哪些治疗方法可能有效治疗儿科癌症。”该项目有三个主要目标。 （1）确定哪种当前UT的小儿癌模型（异种移植物）最类似于cDNA微阵列的起源癌症。 （2）开发该临床前面板的组织和细胞微阵列和蛋白质裂解阵列，目的是识别与癌症相关的分子靶标和信号传导途径，这些靶标和信号通路可能会被治疗，以改善患有癌症的儿童的结果。 （3）将这些组织和蛋白质阵列作为试剂，向壁外研究社区中的合格研究者提供试剂。该项目将通过确定最佳的异种移植模型来促进儿科癌症药物的发展，该模型与原始癌症最相似，并将成为鉴定分子靶标和细胞信号谱的一种资源，以及随后测试新的抗癌药物，以实现其对儿童时期癌症的潜在活性。该资源有可能提高儿童期癌症的新治疗靶标发现的速度，并促进对儿童癌症活跃的新分子靶向剂的临床使用。诸如死亡途径基因之类的靶标，在这些癌症中独特地表达。